London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.
According to the Arix’s Friday announcement, investors include Woodford Investment Management, and pharmaceutical companies UCB S.A. and Takeda’s ventures group, Takeda Ventures.
Joe Anderson, Chief Executive Officer of Arix Bioscience, said such strong demand for Arix’s initial public offering from a such range of investors in this oversubscribed offering means a vote of confidence for the life-science sector. “We have a highly experienced international team and this new capital enables us to continue our commitment to supporting businesses in the vanguard of medical innovation, with the ultimate goal of improving outcomes for patients and unlocking value for investors,” he said.
Interested in Arix’s IPO were groups such as institutional investors, pension funds, family offices, wealth managers and global pharmaceutical companies. Anderson said that the intermediaries offer was also strongly supported by retail investors.
“We believe this demonstrates the growing appeal of this opportunity to convert promising science into important new medicines. We’d like to thank all our existing and new shareholders for their fantastic support and look forward to continued success in the future,” Anderson concluded.